SOD1 and amyotrophic lateral sclerosis: Lastly, although without a primary autoimmune mechanism of action, also following the encouraging results of tofersen in SOD1 ALS patients, a phase 1b/2a trial (FOCUS-C9, NCT04931862) recently tested the effect of antisense oligonucleotides (WVE-004) on C9Orf72 ALS-FTD patients.